AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ANGO

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics (ANGO) reported Q1 revenue growth in NanoKnife, up 29% to $8.3M, with probe sales rising 24.1% and capital sales up 53.5%. The company expects AlphaReturn to expand its product line. Gross margin improved to 59.4%, and adjusted EBITDA increased to $5M. The company reaffirmed its fiscal 2027 outlook, expecting revenue of $336M-$341M and adjusted EBITDA of $13M-$16M.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 2:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Q1 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBullishMed
01

Why it matters

The earnings beat reduces downside risk and may attract short‑term buying, but flat revenue growth tempers enthusiasm.

02

Market read

Earnings release provides fresh data for traders; modest price reaction expected.

03

What to watch

Potential headwinds from tariff uncertainty and reimbursement variability could temper gains.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

AngioDynamics reported Q1 results, highlighting revenue growth, margin expansion, and reaffirmed FY2027 outlook.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Q1 earnings released with narrowed loss, margin expansion, and reaffirmed FY2027 guidance.

Expected impact

likely modest upside as market prices in improved loss and reaffirmed guidance

Evidence & confidence

First‑report earnings with better-than‑expected loss, higher gross margin, and unchanged revenue guidance reduce downside risk.

Market effects

Sector

Improved margins may signal strength for the broader med‑tech device sector.

Regional

Limited to U.S. small‑cap healthcare investors.

Global

Low; impact confined to AngioDynamics and peers.

Counterpoint

What could challenge this read

Loss narrowing may already be priced in; focus on flat revenue growth could limit upside.

Key entities

  • Company
    AngioDynamics, Inc.

    Medical device maker (NASDAQ: ANGO).

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

5 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com